The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney

PLoS Pathogens

Volumn 12, Issue 11, 2016, Pages

  Ramani, Kritika ^a   Garg, Abhishek V ^a   Jawale, Chetan V ^a   Conti, Heather R ^b   Whibley, Natasha ^a   Jackson, Edwin K ^a   Shiva, Sruti S ^a   Horne, William ^c   Kolls, Jay K ^c   Gaffen, Sarah L ^a   Biswas, Partha S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CREATININE; FLUCONAZOLE; INTERLEUKIN 17; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CANDIDA ALBICANS; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; FUNGUS IMMUNITY; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INVASIVE CANDIDIASIS; KALLIKREIN KININ SYSTEM; KIDNEY; KIDNEY FUNCTION; MALE; MICROPHOTOGRAPHY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; TISSUE INJURY; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CANDIDIASIS; DISEASE MODEL; DNA MICROARRAY; IMMUNOLOGY; KIDNEY DISEASE; MICROBIOLOGY;

ANIMALS; BLOTTING, WESTERN; CANDIDIASIS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; KALLIKREIN-KININ SYSTEM; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 85002189001     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005952     Document Type: Article

References (58)

1. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, et al. (2012) Hidden killers: human fungal infections. Sci Transl Med4: 165rv113.
2. Brown GD, Denning DW, Levitz SM, (2012) Tackling human fungal infections. Science336: 647. doi: 10.1126/science.122223622582229
3. Brown GD, Netea MG, (2012) Exciting developments in the immunology of fungal infections. Cell Host Microbe11: 422–424. doi: 10.1016/j.chom.2012.04.01022607795
4. Filler SG, Edwards JE, Jr. (1995) When and how to treat serious candidal infections: concepts and controversies. Curr Clin Top Infect Dis15: 1–18. 7546363
5. Xie JL, Polvi EJ, Shekhar-Guturja T, Cowen LE, (2014) Elucidating drug resistance in human fungal pathogens. Future Microbiol9: 523–542. doi: 10.2217/fmb.14.1824810351
6. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS, (2015) Mechanisms of Antifungal Drug Resistance. Cold Spring Harb Perspect Med5: a019752.
7. Sun S, Li Y, Guo Q, Shi C, Yu J, et al. (2008) In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother52: 409–417. doi: 10.1128/AAC.01070-0718056277
8. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D, (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother44: 2373–2381. 10952582
9. Guo Q, Sun S, Yu J, Li Y, Cao L, (2008) Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J Med Microbiol57: 457–462. doi: 10.1099/jmm.0.47651-018349365
10. Sun L, Sun S, Cheng A, Wu X, Zhang Y, et al. (2009) In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrob Agents Chemother53: 1586–1591. doi: 10.1128/AAC.00940-0819171796
11. Chang W, Li Y, Zhang L, Cheng A, Lou H, (2012) Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PLoS One7: e41624. doi: 10.1371/journal.pone.004162422848547
12. Pfaller MA, Diekema DJ, (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev20: 133–163. doi: 10.1128/CMR.00029-0617223626
13. Lionakis MS, (2014) New insights into innate immune control of systemic candidiasis. Med Mycol52: 555–564. doi: 10.1093/mmy/myu02925023483
14. Huang W, Na L, Fidel PL, Schwarzenberger P, (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis190: 624–631. doi: 10.1086/42232915243941
15. Bar E, Whitney PG, Moor K, Reis e Sousa C, LeibundGut-Landmann S, (2014) IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity40: 117–127. doi: 10.1016/j.immuni.2013.12.00224412614
16. van de Veerdonk FL, Kullberg BJ, Verschueren IC, Hendriks T, van der Meer JW, et al. (2010) Differential effects of IL-17 pathway in disseminated candidiasis and zymosan-induced multiple organ failure. Shock34: 407–411. doi: 10.1097/SHK.0b013e3181d6704120160669
17. Ho AW, Gaffen SL, (2010) IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol32: 33–42. doi: 10.1007/s00281-009-0185-020012905
18. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, et al. (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med206: 299–311. doi: 10.1084/jem.2008146319204111
19. Conti HR, Peterson AC, Brane L, Huppler AR, Hernandez-Santos N, et al. (2014) Oral-resident natural Th17 cells and gammadelta T cells control opportunistic Candida albicans infections. J Exp Med211: 2075–2084. doi: 10.1084/jem.2013087725200028
20. Hillmeister P, Persson PB, (2012) The Kallikrein-Kinin system. Acta Physiol (Oxf)206: 215–219.
21. Kakoki M, Smithies O, (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int75: 1019–1030. doi: 10.1038/ki.2008.64719190676
22. Asakimori Y, Yorioka N, Yamamoto I, Okumoto S, Doi S, et al. (2001) Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease. Nephron89: 219–223. doi: 4607111549906
23. Baboolal K, Ravine D, Daniels J, Coles GA, Williams JD, (1997) Association of the ACE gene deletion polymorphism and early onset of ESRF in PKD1 ADPKD. Kidney International52: 1126–1126.
24. Harden PN, Geddes C, Rowe PA, Mcilroy JH, Boultonjones M, et al. (1995) Polymorphisms in Angiotensin-Converting-Enzyme Gene and Progression of Iga Nephropathy. Lancet345: 1540–1542. 7791440
25. Jozwiak L, Drop A, Buraczynska K, Ksiazek P, Mierzicki P, et al. (2004) Association of the human bradykinin B2 receptor gene with chronic renal failure. Mol Diagn8: 157–161. 15771553
26. Maeda H, Akaike T, Sakata Y, Maruo K, (1993) Role of bradykinin in microbial infection: enhancement of septicemia by microbial proteases and kinin. Agents Actions Suppl42: 159–165. 8356921
27. Rust NM, Papa MP, Scovino AM, da Silva MM, Calzavara-Silva CE, et al. (2012) Bradykinin enhances Sindbis virus infection in human brain microvascular endothelial cells. Virology422: 81–91. doi: 10.1016/j.virol.2011.10.00322047990
28. Bras G, Bochenska O, Rapala-Kozik M, Guevara-Lora I, Faussner A, et al. (2013) Release of biologically active kinin peptides, Met-Lys-bradykinin and Leu-Met-Lys-bradykinin from human kininogens by two major secreted aspartic proteases of Candida parapsilosis. Peptides48: 114–123. doi: 10.1016/j.peptides.2013.08.00323954712
29. Bochenska O, Rapala-Kozik M, Wolak N, Bras G, Kozik A, et al. (2013) Secreted aspartic peptidases of Candida albicans liberate bactericidal hemocidins from human hemoglobin. Peptides48: 49–58. doi: 10.1016/j.peptides.2013.07.02323927842
30. Hwang J, Kita R, Kwon HS, Choi EH, Lee SH, et al. (2011) Epidermal ablation of Dlx3 is linked to IL-17-associated skin inflammation. Proc Natl Acad Sci U S A108: 11566–11571. doi: 10.1073/pnas.101965810821709238
31. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, et al. (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med15: 788–793. doi: 10.1038/nm.198019561616
32. Leunk RD, Moon RJ, (1979) Physiological and metabolic alterations accompanying systemic candidiasis in mice. Infect Immun26: 1035–1041. 393627
33. Garg AV, Amatya N, Chen K, Cruz JA, Grover P, et al. (2015) MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation. Immunity43: 475–487. doi: 10.1016/j.immuni.2015.07.02126320658
34. Orfila C, Bompart G, Lepert JC, Suc JM, Girolami JP, (1993) Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats. Histochem J25: 772–777. 8282570
35. Orfila C, Bompart G, Lepert JC, Suc JM, Girolami JP, (1993) Immunolocalization of renal kallikrein-like substance in rat urinary bladder. Histochem J25: 664–669. 7693624
36. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, et al. (2004) Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem279: 2559–2567. doi: 10.1074/jbc.M30880920014600152
37. Yiu WH, Wong DW, Chan LY, Leung JC, Chan KW, et al. (2014) Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells. PLoS One9: e88894. doi: 10.1371/journal.pone.008889424586431
38. Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I, (2014) Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol165: 119–127. doi: 10.1159/00036840425401373
39. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, et al. (2013) CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest123: 5035–5051. doi: 10.1172/JCI7130724177428
40. Plantinga TS, Hamza OJ, Willment JA, Ferwerda B, van de Geer NM, et al. (2010) Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. J Acquir Immune Defic Syndr55: 87–94. doi: 10.1097/QAI.0b013e3181e53c6420577092
41. Kakoki M, McGarrah RW, Kim HS, Smithies O, (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A104: 7576–7581. doi: 10.1073/pnas.070161710417452647
42. Fan H, Stefkova J, El-Dahr SS, (2006) Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway. Am J Physiol Renal Physiol291: F670–682. doi: 10.1152/ajprenal.00037.200616571598
43. Hammond NA, Nikolaidis P, Miller FH, (2012) Infectious and inflammatory diseases of the kidney. Radiol Clin North Am50: 259–270, vi. doi: 10.1016/j.rcl.2012.02.00222498442
44. Gaffen SL, (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol9: 556–567. doi: 10.1038/nri258619575028
45. Onishi RM, Gaffen SL, (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology129: 311–321. doi: 10.1111/j.1365-2567.2009.03240.x20409152
46. Quintin J, Voigt J, van der Voort R, Jacobsen ID, Verschueren I, et al. (2014) Differential role of NK cells against Candida albicans infection in immunocompetent or immunocompromised mice. Eur J Immunol44: 2405–2414. doi: 10.1002/eji.20134382824802993
47. Ramani K, Pawaria S, Maers K, Huppler AR, Gaffen SL, et al. (2014) An essential role of interleukin-17 receptor signaling in the development of autoimmune glomerulonephritis. J Leukoc Biol96: 463–472. doi: 10.1189/jlb.3A0414-184R24935958
48. Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, et al. (1995) Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J14: 1932–1941. 7744000
49. Simpson-Abelson MR, Childs EE, Ferreira MC, Bishu S, Conti HR, et al. (2015) C/EBPbeta Promotes Immunity to Oral Candidiasis through Regulation of beta-Defensins. PLoS One10: e0136538. doi: 10.1371/journal.pone.013653826317211
50. Park H, Solis NV, Louie JS, Spellberg B, Rodriguez N, et al. (2014) Different tumor necrosis factor alpha antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice. Virulence5: 625–629. doi: 10.4161/viru.2969925007095
51. Moussa L, Apostolopoulos J, Davenport P, Tchongue J, Tipping PG, (2007) Protease-activated receptor-2 augments experimental crescentic glomerulonephritis. Am J Pathol171: 800–808. doi: 10.2353/ajpath.2007.06115517640968
52. Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, et al. (2007) Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood110: 3176–3182. doi: 10.1182/blood-2007-02-07544017641206
53. Dey M, Baldys A, Sumter DB, Gooz P, Luttrell LM, et al. (2010) Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement. J Pharmacol Exp Ther334: 775–783. doi: 10.1124/jpet.110.16805420566668
54. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, et al. (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med371: 326–338. doi: 10.1056/NEJMoa131425825007392
55. Miossec P, Kolls JK, (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov11: 763–776. doi: 10.1038/nrd379423023676
56. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE, 3rd (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest109: 1057–1063. doi: 10.1172/JCI1421111956243
57. MacArthur PH, Shiva S, Gladwin MT, (2007) Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci851: 93–105. doi: 10.1016/j.jchromb.2006.12.01217208057
58. Miyazaki T, Miyazaki Y, Izumikawa K, Kakeya H, Miyakoshi S, et al. (2006) Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob Agents Chemother50: 580–586. doi: 10.1128/AAC.50.2.580-586.200616436713